Expression of checkpoint kinase 2 in breast carcinomas: Correlation with key regulators of tumor cell proliferation, angiogenesis, and survival

Histology and Histopathology

Volumn 21, Issue 4-6, 2006, Pages 373-382

  Ribeiro Silva, Alfredo ^a   Koyota Moutinho, M A ^a   Becker de Moura, H ^a   Ribeiro do Vale, F ^a   Zucoloto, S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast; Carcinoma; Checkpoint kinase 2; Immunohistochemistry; Prognosis

Indexed keywords

ANGIOGENIC FACTOR; ANTIBODY; CHECKPOINT KINASE 2; CYCLOPHOSPHAMIDE; FLUOROURACIL; FORMALDEHYDE; METHOTREXATE; PARAFFIN; PROTEIN P27; TELOMERASE; CYCLINE; DNA BINDING PROTEIN; P27 ANTIGEN; PROTEIN SERINE THREONINE KINASE; TERT PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DNA DAMAGE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; ONCOGENE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE FIXATION; TUMOR CELL; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CELL DEATH; CHEMISTRY; ENZYMOLOGY; GENETICS; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DEATH; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; DNA DAMAGE; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL RATE; TELOMERASE;

EID: 33644845663     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Abd El-Rehim D.M., Pinde, S.E., Paish C.E., Bell J.A., Rampaul R.S., Blamey R.W., Robertson J.F., Nicholson R.I. and Ellis I.O. (2004). Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br. J. Cancer 91, 1532-1542.
2. Ahn J., Urist M. and Prives C. (2004). The Chk2 protein kinase. DNA Repair 3, 1039-1047.
3. Allinen M., Huusko P., Mantyniemi S., Launonen V. and Winqvist R. (2001). Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br. J. Cancer 85, 209-212.
4. Barnes A., Pinder S.E., Bell J.A., Paish E.C., Wencyk P.M., Robertson J.F., Elston C.W. and Ellis I.O. (2003). Expression of p27kip1 in breast cancer and its prognostic significance. J. Pathol. 201, 451-459.
5. Bartkova J., Guldberg P., Gronbaek K., Koed K., Primdahl H., Moller K., Lukas J., Orntoft T.F. and Bartek J. (2004). Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene 23, 8545-8551.
6. Baykal A., Rosen D., Zhou C., Liu J. and Sahin A.A. (2004). Telomerase in breast cancer: a critical evaluation. Adv. Anat. Pathol. 11, 262-268.
7. Bloom H.J.G. and Richardson W.W. (1957). Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer 11, 359-377.
8. Daidone M.G., Paradiso A., Gion M., Harbeck N., Sweep F. and Schmitt M. (2004). Biomolecular features of clinical relevance in breast cancer. Eur. J. Nucl. Med. Mol. Imaging 31, 3-14.
9. De Paola F., Vecci A.M., Granato A.M., Liverani M., Monti F., Innoceta A.M., Gianni L., Saragoni L., Ricci M., Falcini F., Amadori D. and Volpi A. (2002). P27/kip1 expression in normal epithelium, benign and neoplastic breast lesions. J. Pathol. 196, 26-31.
10. Duffy M.J., Maguire T.M., Hill A., McDermott E. and O'Higgins N. (2000). Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2, 252-257.
11. Elston C.W. and Ellis I.O. (1991). Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19, 403-410.
12. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., Ruby S.G., O'Malley F., Simpson J.F., Connolly J.L., Hayes D.F., Edge S.B., Lichter A. and Schnitt S.J. (2000). Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med 124, 966-978.
13. Gils A. and Declerck P.J. (2004). Plasminogen activator inhibitor-1. Curr. Med. Chem. 11, 2323-2334.
14. Ikeda S., Shibata T., Eishi Y., Takizawa T. and Koike M. (2003). Correlation between the expression of telomerase reverse transcriptase and proliferative activity in breast cancer cells using an immunocytochemical regaining method. Pathol. Int. 53, 762-768.
15. Ingvarsson S., Sigbjornsdottir B.I., Huiping C., Hafsteinsdottir S.H., Ragnarsson G., Barkardottir R.B., Arason A., Egilsson V. and Bergthorsson J.T. (2002). Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res. 4, R4.
16. Jekimovs C.R., Chen X., Arnold J., Gatei M., Richard D.J., Spurdle A.B., Khanna K.K., Chenevix-Trench G. and kConFab Investigators. (2005). Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals. Br. J. Cancer 92, 784-790.
17. Kato N., Fujimoto H., Yoda A., Oishi I., Matsumura N., Kondo T., Tsukada J., Tanaka Y., Imamura M. and Minami Y. (2004). Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines. Cell. Death Differ. 11, 153-161.
18. Kilpivaara O., Bartkova J., Eerola H., Syrjakoski K., Vahteristo P., Lukas J., Blomqvist C., Holli K., Heikkila P., Sauter G., Kallioniemi O.P., Bartek J. and Nevanlinna H. (2005). Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int. J. Cancer 113, 575-580.
19. Kirkpatrick K.L., Clark G., Ghilchick M., Newbold R.F. and Mokbel K. (2003). hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur. J. Surg. Oncol. 29, 321-326.
20. Kirkpatrick K.L., Newbold R.F. and Mokbel K. (2004). The mRNA expression of hTERT in human breast carcinomas correlates with VEGF expression. J. Carcinog. 3, 1.
21. Lebeau A., Unholzer A., Amann G., Kronawitter M., Bauerfeind I., Sendelhofert A., Iff A. and Lohrs U. (2003). EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 79, 187-198.
22. Liu J., Baykal A., Fung K.M., Thompson-Lanza J.A., Hoque A., Lippman S.M. and Sahin A. (2004). Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Int. J. Oncol. 24, 879-884.
23. Meiiers-Heijboer H., van den Ouweland A., Klijn J., Wasielewski M., de Snoo A., Oldenburg R., Hollestelle A., Houben M., Crepin E., van Veghel-Plandsoen M., Elstrodt F., van Duijn C., Bartels C., Meijers C., Schutte M., McGuffog L., Thompson D., Easton D., Sodha N., Seal S., Barfoot R., Mangion J., Chang-Claude J., Eccles D., Eeles R., Evans D.G., Houlston R., Murday V., Narod S., Peretz T., Peto J., Phelan C., Zhang H.X., Szabo C., Devilee P., Goldgar D., Futreal P.A., Nathanson K.L., Weber B., Rahman N., Stratton M.R. and CHEK2-Breast Cancer Consortium. (2002). Low-penetrance susceptibility to breast cancer due to CHEK2()1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31, 55-59.
24. Matsuoka S., Huang M. and Elledge S.J. (1998). Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893-1897.
25. Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K. and Elledge S.J. (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. USA 97, 10389-10394.
26. Milde-Langosch K., Bamberger A.M., Methner C., Rieck G. and Loning T. (2000). Expression of cell cycle-regulatory proteins rb, p16/MTS1, P27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int. J. Cancer 87, 468-472.
27. Miller C.W., Ikezoe T., Krug U., Hofmann W.K., Tavor S., Vegesna V., Tsukasaki K., Takeuchi S. and Koeffler H.P. (2002). Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 33, 17-21.
28. Mokbel K., Parris C.N., Ghilchik M., Williams G. and Newbold R.F. (1999). The association between telomerase, histopathological parameters, and KI-67 expression in breast cancer. Am. J. Surg. 178, 69-72.
29. Nieto A., Perez-Alenza M.D., Del Castillo N., Tabanera E., Castano M. and Pena L. (2003). BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables. J. Comp. Pathol. 128, 260-268.
30. Poremba C., Heine B., Diallo R., Heinecke A., Wai D., Schaefer K.L., Braun Y., Schuck A., Lanvers C., Bankfalvi A., Kneif S., Torhorst J., Zuber M., Kochli O.R., Mross F., Dieterich H., Sauter G., Stein H., Fogt F. and Boecker W. (2002) Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J. Pathol. 198, 181-189.
31. Rhodes A., Jasani B., Anderson E., Dodson A.R. and Balaton A.J. (2002). Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am. J. Clin. Pathol. 118, 408-417.
32. Ribeiro-Silva A., Ramalho L.N.Z., Garcia S.B. and Zucoloto S. (2003). The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch. Pathol. Lab. Med. 127, 336-340.
33. Rieger P.T. (2004). The biology of cancer genetics. Semin. Oncol. Nurs. 20, 145-54.
34. Schneider B.P. and Miller K.D. (2005). Angiogenesis of breast cancer. J. Clin. Oncol. 23, 1782-1790.
35. Singh M., Parnes M.B., Spoelstra N., Bleile M.J. and Robinson W.A. (2004). p16 expression in sentinel nodes with metastatic breast carcinoma: evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis. Hum. Pathol. 35, 1524-1530.
36. Sirvent J.J., Aguilar M.C., Olona M., Pelegri A., Blazquez S. and Gutierrez C. (2004). Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study. Histol. Histopathol. 19, 759-770.
37. Sledge G.W. Jr. (2002). Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin. Oncol. 29, 104-110.
38. Staalesen V., Falck J., Geisler S., Bartkova J., Borresen-Dale A.L., Lukas J., Lillehaug J.R., Bartek J. and Lonning P.E. (2004). Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 23, 8535-8544.
39. Sullivan A., Yuille M., Repellin C., Reddy A., Reelfs O., Bell A., Dunne B., Gusterson B.A., Osin P., Farrell P.J., Yulug I., Evans A., Ozcelik T., Gasco M. and Crook T. (2002). Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 21, 1316-1324.
40. Syrjakoski K., Kuukasjarvi T., Auvinen A. and Kallioniemi O.P. (2004). CHEK2 1100delC is not a risk factor for male breast cancer population. Int. J. Cancer 108, 475-476.
41. Tang Y., Nakada M.T., Kesavan P., McCabe F., Millar H., Rafferty P., Bugelski P., and Yan L. (2005). Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 65, 3193-3199.
42. Tauchi T., Shin-Ya K., Sashida G., Sumi M., Nakajima A., Shimamoto T., Ohyashiki J.H. and Ohyashiki K. (2003). Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 22, 5338-5347.
43. Tort F., Hernandez S., Bea S., Martinez A., Esteller M., Herman J.G., Puig X., Camacho E., Sanchez M., Nayach I., Lopez-Guillermo A., Fernandez P.L., Colomer D., Hernandez L. and Campo E. (2002). CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 100, 4602-4608.
44. Troncone G., Migliaccio I., Caleo A., Palmieri E.A., Iaccarino A., Sparano L., Vetrani A. and Palombini L. (2004). p27(Kip1) expression and grading of breast cancer diagnosed on cytological samples. Diagn. Cytopathol. 30, 375-380.
45. Umekita Y., Chi Y., Sagara Y. and Yoshida H. (2002). Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int. J. Cancer 98, 415-418.
46. Vahteristo P., Bartkova J., Eerola H., Syrjakoski K., Ojala S., Kilpivaara O., Tamminen A., Kononen J., Aittomaki K., Heikkila P., Holli K., Blomqvist C., Bartek J., Kallioniemi O.P. and Nevanlinna H. (2002). A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 71, 432-438.
47. Wai L.K. (2004). Telomeres, telomerase, and tumorigenesis: a review. MedGenMed. 6, 19.
48. Walworth N., Davey S. and Beach D. (1993). Fission yeast chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature 363, 368-371.
49. Yano Y., Yoshida K., Osaki A., Toge T., Tahara H., Ide T. and Yasui W. (2002) Expression and distribution of human telomerase catalytic component, hTERT, in human breast tissues. Anticancer Res. 22, 4101-4107.
50. Zhang P., Wang J., Gao W., Yuan B.Z., Rogers J. and Reed E. (2004). CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol. Cancer 3, 14.